key: cord-1029075-5qi8x9ie
authors: Zeng, Huadong; Deng, Shaodong; Zhou, Zhou; Qiu, Xian; Jia, Xingwang; Li, Zhikui; Wang, Jun; Duan, Honglu; Tu, Li; Wang, Junli
title: Diagnostic value of combined nucleic acid and antibody detection in suspected COVID-19 cases
date: 2020-07-10
journal: Public Health
DOI: 10.1016/j.puhe.2020.07.011
sha: dd259c8e17467c1004dc9cb079fafc3dc85dac07
doc_id: 1029075
cord_uid: 5qi8x9ie

Abstract Objectives Nucleic acid testing is the gold-standard method for the diagnosis of coronavirus disease 2019 (COVID-19); however, large numbers of false-negative results have been reported. In this study, nucleic acid detection and antibody detection (IgG and IgM) were combined in order to improve the testing accuracy of suspected COVID-19 patients. Study design xxxx Methods A total of 71 suspected COVID-19 patients were selected to participate in this study, which included a retrospective analysis of clinical features, imaging examination, laboratory biochemical examination, and nucleic acid detection and specific antibody (IgM and IgG) detection. Results The majority of participants with suspected COVID-19 presented with fever (67.61%) and cough (54.93%), and imaging results showed multiple small patches and ground-glass opacity in both lungs, with less common infiltration and consolidation opacity (23.94%). Routine blood tests were mostly normal (69.01%), while only a few patients had lymphopenia (4.23%) or leukopenia (12.68%). There was no statistical difference in the double-positive rate between nucleic acid detection (46.48%) and specific antibody (IgG and IgM) detection (42.25%) (P = 0.612); both of which were also poorly consistent with each other (Kappa = 0.231). The positive rate of combined nucleic acid detection and antibody detection (63.38%) was significantly increased, compared with that of nucleic acid detection (46.48%) and that of specific antibody (IgG and IgM) detection (42.25%), and the differences were statistically significant (P = 0.043 and P = 0.012, respectively). Conclusions Nucleic acid detection and specific antibody (IgG and IgM) detection had similar positive rates, and their combination could improve the positive rate of COVID-19 detection, which is of great significance for diagnosis and epidemic control.

Coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a new acute respiratory infectious disease, which first occurred in December 2019 in Wuhan, Hubei Province, China. COVID-19 quickly spread to several cities in other provinces in China, such as Shenzhen in Guangdong Province, and subsequently many countries around the world, causing wide concern [1] . By early March 2020, more than 80,000 cases had been confirmed in China, with more than 30,000 deaths; in addition, there were more than 30,000 cases outside of China, with more than 700 deaths, mainly distributed in South Korea, Iran, Italy and France.

The majority of patients experienced mild symptoms, with the death rate of about 2.38%, which mainly consisted of elderly men with underlying health conditions.

To date, the global pandemic is not yet under complete control. SARS-CoV-2 is mainly transmitted by respiratory droplet transmission, airborne transmission, contract transmission, faeces-mouth transmission and even maternal-foetal transmission [2] . Currently, there is no treatment for COVID-19 and therefore patients rely on support and alleviation of the symptoms to recover. The Chinese Center for Disease Control and Prevention (CDC) has designated COVID-19 as a 'Class B' infectious disease and recommends following prevention and control measures for 'Class A' infectious diseases, focusing on early diagnosis and early isolation to cut-off the source of infection [3] . At present, the standard method for the diagnosis and control of the epidemic is real-time fluorescent reverse transcription polymerase chain reaction (RT-PCR) nucleic acid detection, which is highly specific and can immediately determine whether patients are infected with SARS-CoV-2 or not.

However, nucleic acid detection from nasopharyngeal swabs showed high false-negative rates in clinical application, producing a number of suspected COVID-19 patients [4] . It is very important to improve the diagnosis rate of suspected cases to ensure timely treatment for confirmed COVID-19 patients to avoid the spread of infection, but also to avoid the overtreatment of non-COVID patients thus reducing human and material resources. In this study, retrospective analysis was performed on 71 suspected COVID-19 cases, combined with nucleic acid detection, laboratory biochemical examination, imaging examination and specific antibody (IgG and IgM) detection, which can provide a clinical basis for improving the diagnosis of suspected COVID-19 cases.

A total of 71 suspected COVID-19 patients, ranging in age from 2 to 65 years 

This study was approved by the Ethics Committee of Shenzhen Hospital, Southern Medical University (NYSZYYEC20200009).

Two sterile swabs were used to wipe both pharyngeal tonsils and the posterior pharyngeal wall simultaneously. Then, the swab head was immersed in a tube with 3 ml of virus preservation solution, the tube cover was tightened and the specimen was sealed in an appropriate plastic bag to avoid cross contamination. All tests were completed within 24 h of swab collection. Nucleic 

Biotechnologies Co., ltd.) were used for testing 3-4 weeks after COVID-19 infection, and were verified and approved by BIMT. Whole blood samples of suspected patients were collected and heparin was added for anticoagulation.

The tests were completed within 24 h of blood sample collection. According to the instructions, 20 µl of the sample was added to a tube with phosphate-buffered saline (PBS) buffer. After homogeneously mixing, 80 µl of mixture was added into the hole of the test card. The test card is composed of a card cover and a test strip; the test strip contains sample stage, glass fibre, cellulose nitrate film, IgG or IgM antibody, etc. After reaction for 15 min, the relative content of IgG or IgM was detected under a fluorescence immunoassay analyser. IgM ＞0.88 µ/L and IgG ＞1.00 µ/L were defined as positive results based on the detection values from 242 healthy subjects, and the 95% confidence interval was labelled as negative.

SPSS Version 26.0 software was used. Count data were expressed using percentage. The χ 2 (chi-square test) was used for comparison between groups. p ＜ 0.05 displayed statistical significance.

A total of 71 suspected COVID-19 patients, ranging in age from 2 to 65 years Table 1 ).

The majority of patients presented with fever (67.61%) and cough (54.93%), while a few had fatigue and shortness of breath, and some had diarrhoea, sore throats and other symptoms. Imaging findings showed multiple small patches and ground-glass opacity in both lungs, with less common infiltration and consolidation opacity (23.94%); chest computed tomography (CT) scans of some patients were normal (14.08%). Routine blood tests were mostly normal in the early stages (69.01%), while a few patients had lymphopenia (4.23%), leukopenia (12.68%), leukocytosis (14.08%) and neutrophilic leukocytosis (14.08%) (see Table 2 ).

The incubation period of SARS-CoV-2 infection is generally 3-7 days. Patients 

Analysis showed that the positive detection rate of COVID-19 was 63.38% in the combined nucleic acid detection and antibody detection, compared with 46.48% in single nucleic acid detection and 42.25% in single specific antibody detection; thus, the diagnosis rate was increased by about 20% and the difference was statistically significant (p = 0.043 and p = 0.012, respectively; see Table 4 ).

SARS-CoV-2 is the seventh new human coronavirus discovered so far, which belongs to β coronavirus family and has a high homology with the SARS-CoV epidemic in 2003. Such viruses belong to the RNA virus family, which evolves quickly, mutates greatly and is highly infectious, with a latency of generally 3-7 days, ranging from 1 to 24 days [5, 6] . SARS-CoV-2 nucleic acid detection is a key technical support to help prevent and control the COVID-19 epidemic. The analysis targets the unique genetic sequence of the virus by adopting real-time quantitative PCR, which is an established and easy to carry out test. Therefore, nucleic acid detection plays an important role in early diagnosis, isolation and treatment [7] . Patients test positive when the dual-target is positive in nucleic acid detection; however, some individuals have a single-target positive result in nucleic acid detection, thus receive a negative test result, even though they may be infected -in these circumstances, multiple detections should be conducted. However, it needs to be emphasised that nucleic acid detection cannot be used as the golden standard for the diagnosis of COVID-19, and that As a helpful complement to the nucleic acid detection of SARS-CoV-2, chest CT typically manifests as multiple ground-glass opacity, patch opacity and consolidation opacity, and the combination of chest CT with nucleic acid detection in nasopharyngeal swabs can effectively improve the diagnosis rate of SARS-CoV-2 [8] . A previous report showed that the positive detection rate of CT can improve the diagnosis rate of SARS-CoV-2 [9] . In addition, another study showed that of 1014 patients, only 59% tested positive using nucleic acid detection, while 88% were positive with chest CT, and 308 patients were negative in nucleic acid detection, but positive in chest CT [10] . This indicates that chest CT has a significant sensitivity for the diagnosis of SARS-CoV-2 compared with nucleic acid detection in nasopharyngeal swab. The CT results of 71 suspected cases in the current study showed that 23.94% of patients had typical changes in both lungs, and these changes needed to be differentiated from other virus pneumonia, such as influenza A, influenza B and adenovirus pneumonia. It was speculated that all of our clinical cases were caused by mild or common symptoms rather than severe disease. Therefore, the CT results can be used to assistant judgements but are not recommended as diagnostic standard. Laboratory biochemical examination showed that the routine blood tests such as transaminase, creatine kinase, myoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin (IL)-6 levels were increased; lymphocyte count and albumin were decreased; procalcitonin was normal, etc., which were helpful to determine whether the disease contained bacterial infection, oxidative disorder, and prognosis and outcome [11] .

However, it was shown in this study that most indicators were normal at the early stage (69.01%), while a few patients had lymphopenia and leukopenia However, IgG can be detected on day 7 after infection, peaks on day 25 and the level remains high for several months [12] . In addition, it was also reported that during days 0-40 after infection, IgG and IgM are simultaneously detected and share the same peak times, as well as the decreasing trend [13] . Specific double-positive antibody (IgM and IgG) can diagnose SARS-CoV-2 infection according to the novel coronavirus pneumonia diagnosis and treatment plan (Trial Seventh Edition). Antibody detection is used to detect antibodies in peripheral blood samples collected in a controllable way, using automatic chemiluminescence immunoassay with high flux and high speed, which can be carried out in all hospitals without the need for specially trained professionals.

At the critical stage of epidemic prevention and control, antibody detection can not only decrease the number of patients misdiagnosed as a result of false-negative nucleic acid detection and improve the diagnosis rate of SARS-CoV-2 infection, but can also avoid the spread of infection by repeated collection of nasopharyngeal swab samples. A previous study showed that on the day of the first blood sampling from 16 COVID-19 patients, the positive rates of IgM and IgG were 50% and 81%, respectively. Moreover, the positive rates of IgM and IgG were 81% and 100% on the fifth day [14] . Among 139 confirmed COVID-19 patients, the positive rates of IgM during week 1, weeks 1-2 and >2 weeks were 27.8%, 48.0% and 95.0%, respectively; while those of IgG were 3.3%, 8.0% and 62.5%, respectively [15] . The detection of antibodies on days 17-23 for 41 COVID-19 patients demonstrated that the positive detection rates for IgG and IgM were 97.6% and 87.8%, respectively [16] . The fast detection kit of Orient Gene Biotech was used to detect 102 COVID-19 patients within 3-4 weeks. It was found that both positive rates for IgG and IgM reached above 95% [17] , indicating high consistency of positive IgM and IgG. In addition, another report of 68 suspected COVID-19 patients showed that 22 cases were positive using nucleic acid detection and 31 were positive for both IgM and IgG testing [13] , which indicated that detection of specific antibody for COVID-19 is more advantageous. In this study, specific antibody (IgG and IgM) detection for 71 suspected cases illustrated that the double-positive rate was 42.25% 3-4 weeks after infection; in addition, among 33 patients who tested positive in nucleic acid detection, 18 were double-positive in antibody detection, and the other 15 were single-positive in IgG (n = 10) or IgM (n = 5) antibody detection. This may be a result of individual differences in the immune response, which can also vary by age age; [18] thus dynamic monitoring is recommended. Additionally, according to the test instructions of the IgM/IgG kit, a high titre of IgM may lead to negative results of IgG detection; similarly, a high titre of IgG can also result in negative IgM results. In this study, 3 cases exhibited this situation. Moreover, negative test results can also be seen when IgG or IgM levels in the blood are lower than the bottom threshold of the test kit (specificity, sensitivity and judgement criteria). In addition, blood sample contamination, different detection units, different operation experience and instruments may also contribute to a difference in the results [19] . Furthermore, a false-positive result may occur when the detection result is susceptible to some interfering substances (e.g. other interferons, rheumatoid factor or nonspecific IgM) and cross-recognition reactions (e.g. SARS-CoV, NL63, OC43, 229 E and HKU1) in the blood samples [20] . The false-positive rates were 0.5% for IgM and 1.0% for IgG in healthy blood samples [21] . It was also reported that the IgM and IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test as a diagnostic criterion [22] . Further analysis showed that the positive rate of SARS-CoV-2 in combined nucleic acid detection and antibody kit detection reached 63.38%, which greatly increases the diagnosis rate.

In suspected COVID-19 cases, nucleic acid detection and specific antibody (IgG and IgM) detection showed a similar positive rate, and their combination could greatly improve the positive rate of diagnosis, which is of great significance for diagnosis and epidemic control. 

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Patterns of IgG and IgM antibody response in COVID-19 patients

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Evaluation of COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling

Coronavirus Infections-More Than Just the Common Cold

Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Characteristics of 71 suspected COVID-19 patients were analysed

Fever (67.61%) and cough (54.93%) were the most common symptoms at the onset of illness

No statistical difference observed in positive rate between nucleic acid (46.48%) and specific antibody (IgG and IgM) (42.25%) detection

Combined nucleic acid and antibody detection could help to improve the positive rate of COVID-19 (63.38%) diagnosis

This study was approved by the Ethics Committee of Shenzhen Hospital, Southern Medical University (NYSZYYEC20200009).

This work was supported by no specific grant.

None declared.